Recent research have focused on the convergence of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and DA signaling. While GCGR stimulators are commonly employed for addressing type 2 diabetes mellitus, their emerging effects on reward circuits, specifically influenced by DA syste